Early-onset absence epilepsy: SLC2A1 gene analysis and treatment evolution

Area of Science:

• Pediatric Neurology
• Clinical Genetics
• Epilepsy Research

Background:

• Early-onset absence epilepsy (EOAE) is a challenging epilepsy syndrome in children.
• The role of the SLC2A1 gene in EOAE requires further investigation.
• Understanding genetic factors may guide treatment strategies for EOAE.

Purpose of the Study:

• To determine the prevalence of SLC2A1 gene mutations in children diagnosed with EOAE.
• To compare demographic and electroclinical features between EOAE patients achieving seizure control with monotherapy versus those requiring add-on anti-epileptic drug (AED) treatment.

Main Methods:

• A cohort of 84 children with strictly defined EOAE from Italian epilepsy centers was analyzed.
• Mutation analysis of the SLC2A1 gene was performed for all participants.
• Demographic and electroclinical data were retrospectively collected and compared between treatment groups.

Main Results:

• No SLC2A1 mutations were identified in any of the children with EOAE.
• No significant differences were observed in demographic or electroclinical variables between the monotherapy and add-on AED groups.
• Children who responded to monotherapy had a significantly shorter mean duration of active epilepsy compared to those requiring add-on treatment.

Conclusions:

• The SLC2A1 gene is unlikely to be a common cause of EOAE in children with a rigorous diagnosis.
• Treatment response in EOAE appears independent of SLC2A1 mutations, with seizure duration being a key differentiator between treatment groups.